Suvretta Capital Management LLC increased its holdings in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 422.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,829,053 shares of the biotechnology company's stock after purchasing an additional 7,137,763 shares during the quarter. Benitec Biopharma makes up 2.6% of Suvretta Capital Management LLC's investment portfolio, making the stock its 8th biggest holding. Suvretta Capital Management LLC owned approximately 83.64% of Benitec Biopharma worth $81,139,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of BNTC. GAMMA Investing LLC increased its position in Benitec Biopharma by 20.3% during the 3rd quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company's stock valued at $60,000 after purchasing an additional 1,102 shares during the period. Acuta Capital Partners LLC bought a new stake in shares of Benitec Biopharma in the 3rd quarter valued at $274,000. Simplify Asset Management Inc. acquired a new stake in shares of Benitec Biopharma during the second quarter worth $358,000. Janus Henderson Group PLC raised its stake in Benitec Biopharma by 35.5% during the first quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company's stock worth $1,266,000 after buying an additional 64,092 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new position in Benitec Biopharma in the second quarter valued at $5,881,000. 52.19% of the stock is currently owned by institutional investors and hedge funds.
Benitec Biopharma Stock Performance
Benitec Biopharma stock traded up $0.36 during midday trading on Friday, reaching $10.09. The stock had a trading volume of 65,150 shares, compared to its average volume of 45,274. Benitec Biopharma Inc. has a 12 month low of $2.69 and a 12 month high of $12.89. The company has a fifty day moving average price of $10.19 and a two-hundred day moving average price of $9.13.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on BNTC. Oppenheimer began coverage on Benitec Biopharma in a report on Wednesday, October 16th. They set an "outperform" rating and a $35.00 price target for the company. Piper Sandler reaffirmed an "overweight" rating on shares of Benitec Biopharma in a research note on Friday, October 18th. JMP Securities lifted their target price on Benitec Biopharma from $16.00 to $18.00 and gave the stock a "market outperform" rating in a report on Monday, October 14th. Finally, Guggenheim began coverage on Benitec Biopharma in a report on Thursday, September 12th. They set a "buy" rating and a $17.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $22.60.
Read Our Latest Research Report on Benitec Biopharma
About Benitec Biopharma
(
Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Read More
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.